Third quarter 2026
Filed Nov 4, 2026Viemed Healthcare Announces Third Quarter 2026 Financial Results
Record quarterly revenue of $80.7 million grew 12.2% year over year and 3.3% sequentially, while attributable net income and Adjusted EBITDA increased sequentially. The company raised the low end of revenue guidance, narrowed Adjusted EBITDA guidance, and lowered its net capital expenditure outlook.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Revenue, three months ended September 30, 2026GAAP | $80.67M | 3.3% | 12.2% |
| Revenue, nine months ended September 30, 2026GAAP | $234.2M | – | – |
| Cost of revenue, three months ended September 30, 2026GAAP | $34.48M | – | – |
| Cost of revenue, nine months ended September 30, 2026GAAP | $100.1M | – | – |
| Gross profit, three months ended September 30, 2026GAAP | $46.19M | – | – |
| Gross profit, nine months ended September 30, 2026GAAP | $134.1M | – | – |
| Selling, general and administrative expense, three months ended September 30, 2026GAAP | $35.51M | – | – |
| Selling, general and administrative expense, nine months ended September 30, 2026GAAP | $107.4M | – | – |
| Research and development expense, three months ended September 30, 2026GAAP | $501K | – | – |
| Research and development expense, nine months ended September 30, 2026GAAP | $1.58M | – | – |
| Stock-based compensation, three months ended September 30, 2026GAAP | $2.48M | – | – |
| Stock-based compensation, nine months ended September 30, 2026GAAP | $6.96M | – | – |
| Income from operations, three months ended September 30, 2026GAAP | $6.96M | – | – |
| Income from operations, nine months ended September 30, 2026GAAP | $15.72M | – | – |
| Net income, three months ended September 30, 2026GAAP | $4.74M | – | – |
| Net income, nine months ended September 30, 2026GAAP | $10.35M | – | – |
| Net income attributable to Viemed Healthcare, Inc., three months ended September 30, 2026GAAP | $4.64M | 67.8% | 32.0% |
| Net income attributable to Viemed Healthcare, Inc., nine months ended September 30, 2026GAAP | $9.98M | – | – |
| Diluted net income per share, three months ended September 30, 2026GAAP | $ 0.11 | – | – |
| Diluted net income per share, nine months ended September 30, 2026GAAP | $ 0.24 | – | – |
| Adjusted EBITDA, quarter ended September 30, 2026non-GAAP | $17.06M | 24.4% | 5.8% |
| Adjusted EBITDA as a percentage of net revenue, quarter ended September 30, 2026non-GAAP | 21.1% | approximately 350 basis points | – |
| Net cash provided by operating activities, nine months ended September 30, 2026GAAP | $35.46M | – | – |
| Net cash provided by operating activities, quarter ended September 30, 2026GAAP | $11.49M | – | – |
| Net cash provided by operating activities, trailing twelve months ended September 30, 2026GAAP | $53.90M | – | – |
| Free cash flow, quarter ended September 30, 2026non-GAAP | $4.03M | – | – |
| Free cash flow, trailing twelve months ended September 30, 2026non-GAAP | $26.06M | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| Ventilator rental revenueSupported by higher average patient volumes. | $37.5M | – | 7.4% |
Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.
Full year ending December 31, 2026 outlook
- Revenue$316 million to $320 million
- NoteAdjusted EBITDA is expected to range from $64 million to $66 million.
- NoteNet capital expenditures are now expected to range from 8.0% to 9.0% of net revenue.
- NoteThis outlook excludes the impact of potential future acquisitions or other strategic transactions.
Capital returns
- During the quarter, the Company repaid $2.1 million of term debt.
- During the quarter, the Company repurchased 115,000 common shares for approximately $1.0 million (excluding taxes).
- Payments for share repurchase programs were $ 7,738 (Expressed in thousands of U.S. Dollars) for the nine months ended September 30, 2026.
- Shares redeemed to pay income tax were $ 2,082 (Expressed in thousands of U.S. Dollars) for the nine months ended September 30, 2026.
What drove it
- Ventilator rental revenue was supported by higher average patient volumes.
- PAP therapy patients increased 37.5% year over year and 16.0% sequentially to 43,861 during the third quarter.
- Sleep resupply patients increased 22.1% year over year and 10.5% sequentially to 40,918.
- The company cited continued growth across its respiratory, sleep, and women's health businesses.
- The updated outlook reflects reduced capital intensity as less capital-intensive product and service offerings contribute a greater share of revenue.
Concerns
- Adjusted EBITDA increased 5.8% year over year, below the 12.2% year-over-year increase in quarterly net revenue.
- Net cash provided by operating activities was $ 35,460 (Expressed in thousands of U.S. Dollars) for the nine months ended September 30, 2026, while accounts receivable, net changed by $ (9,301) (Expressed in thousands of U.S. Dollars).
- The company narrowed its Adjusted EBITDA guidance range to $64 million to $66 million from the previous range of $64 million to $68 million.
- Cash and cash equivalents declined to $ 9,676 (Expressed in thousands of U.S. Dollars) at September 30, 2026 from $ 13,501 (Expressed in thousands of U.S. Dollars) at December 31, 2025.
What to watch
- Whether the anticipated sequential improvement in revenue and Adjusted EBITDA in the fourth quarter is delivered.
- Ventilator patient volumes, which totaled 12,552 as of September 30, 2026.
- Growth in PAP therapy and sleep resupply patient counts.
- Execution of the 8.0% to 9.0% of net revenue net capital expenditure outlook.
- Progress in operating efficiency initiatives and the contribution of less capital-intensive offerings.
Balance sheet and cash flow
- Cash and cash equivalents were $ 9,676 (Expressed in thousands of U.S. Dollars) at September 30, 2026, compared with $ 13,501 (Expressed in thousands of U.S. Dollars) at December 31, 2025.
- Working capital was $12.0 million at September 30, 2026.
- Approximately $46 million was available under existing credit facilities at September 30, 2026.
- Current portion of long-term debt was $ 511 (Expressed in thousands of U.S. Dollars) and long-term debt was $ 4,510 (Expressed in thousands of U.S. Dollars) at September 30, 2026.
- Purchase of property and equipment was $ 23,788 (Expressed in thousands of U.S. Dollars) for the nine months ended September 30, 2026, compared with $ 31,248 (Expressed in thousands of U.S. Dollars) in the prior-year period.
- Net CAPEX was $ 7,462 (Expressed in thousands of U.S. Dollars) for the quarter ended September 30, 2026 and $ 27,845 (Expressed in thousands of U.S. Dollars) for the trailing twelve months ended September 30, 2026.
Analysis
Viemed reported record third-quarter net revenue of $80.7 million, up 12.2% from the prior-year quarter and 3.3% sequentially. The company attributed performance to continued growth across respiratory, sleep, and women's health businesses. Ventilator rental revenue rose 7.4% year over year to $37.5 million, supported by higher average patient volumes, while the period-end ventilator patient count was 12,552.
Patient growth was strongest in the newer sleep-related metrics disclosed. PAP therapy patients increased 37.5% year over year and 16.0% sequentially to 43,861, and sleep resupply patients increased 22.1% year over year and 10.5% sequentially to 40,918. These metrics accompany management's description of a diversified platform and its statement that less capital-intensive offerings are contributing a greater share of revenue.
Profitability improved sequentially. Net income attributable to Viemed was $ 4,638 (Expressed in thousands of U.S. Dollars), compared with $ 2,764 (Expressed in thousands of U.S. Dollars) in the preceding quarter, and Adjusted EBITDA was $ 17,057 (Expressed in thousands of U.S. Dollars), compared with $ 13,715 (Expressed in thousands of U.S. Dollars). Adjusted EBITDA as a percentage of net revenue rose to 21.1% from 17.6%. Year over year, however, Adjusted EBITDA increased 5.8%, while quarterly net revenue increased 12.2%.
Cash generation included $ 11,487 (Expressed in thousands of U.S. Dollars) of quarterly operating cash flow and $ 4,025 (Expressed in thousands of U.S. Dollars) of quarterly free cash flow. The company ended the quarter with $ 9,676 (Expressed in thousands of U.S. Dollars) of cash and cash equivalents, repaid $2.1 million of term debt during the quarter, and repurchased 115,000 common shares for approximately $1.0 million excluding taxes.
The company raised the low end of its full-year net revenue range to $316 million to $320 million from $314 million to $320 million. It narrowed Adjusted EBITDA guidance to $64 million to $66 million from $64 million to $68 million and reduced its net capital expenditure outlook to 8.0% to 9.0% of net revenue from 8.5% to 10.0%. Management expects sequential improvement in both revenue and Adjusted EBITDA in the fourth quarter.
Management, verbatim
Viemed delivered another record quarter, with revenue reaching $80.7 million and continued growth across our respiratory, sleep, and women's health businesses. This marks our first full year-over-year quarterly comparison following the Lehan acquisition, and achieving double-digit revenue growth underscores the strength of our increasingly diversified platform and the opportunities ahead of us.
Casey Hoyt, CEO
We are particularly pleased with the improvement in profitability this quarter. Our attributable net income increased 68% sequentially, while Adjusted EBITDA grew 24%, significantly outpacing revenue growth and demonstrating improved operating leverage. These results reflect the progress we anticipated following our investments earlier this year, and we see additional opportunities to improve efficiency as those initiatives mature. We remain focused on expanding our reach, delivering high-quality patient care, and building on this momentum as we finish the year.
Casey Hoyt, CEO
Not in the filing
stated, not guessed- GAAP gross margin was not reported.
- Quarterly GAAP operating cash flow for the prior-year quarter was not reported.
- Quarterly free cash flow for the prior-year quarter was not reported.
- GAAP EPS sequential comparison was not reported.
- Segment revenue beyond ventilator rental revenue was not reported.
- Dividend information was not reported.
- A GAAP reconciliation for full-year Adjusted EBITDA guidance was not available without unreasonable effort, as stated by the company.
- The previous outlook covered the full year 2026 only, and this quarterly release cannot be compared with full-year guidance.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.